Covalon Technologies Ltd. (COV.V)
CAD 3.44
(2.99%)
CAD 3.44
(2.99%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -4.46 Million CAD | 53.84% |
| 2022 | -9.66 Million CAD | -141.16% |
| 2021 | 23.47 Million CAD | 437.69% |
| 2020 | -6.95 Million CAD | 23.92% |
| 2019 | -9.13 Million CAD | -664.88% |
| 2018 | 1.61 Million CAD | -10.71% |
| 2017 | 1.81 Million CAD | 158.53% |
| 2016 | -3.09 Million CAD | -228.58% |
| 2015 | -941.99 Thousand CAD | -139.22% |
| 2014 | 2.4 Million CAD | 341.83% |
| 2013 | -993.16 Thousand CAD | 75.12% |
| 2012 | -3.99 Million CAD | -12.06% |
| 2011 | -3.56 Million CAD | 9.48% |
| 2010 | -3.93 Million CAD | 19.28% |
| 2009 | -4.87 Million CAD | -30.31% |
| 2008 | -3.74 Million CAD | -21.6% |
| 2007 | -3.07 Million CAD | -39.52% |
| 2006 | -2.2 Million CAD | -18.45% |
| 2005 | -1.86 Million CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -851.54 Thousand CAD | 70.44% |
| 2024 Q2 | 1.46 Million CAD | 271.5% |
| 2024 Q3 | 1.44 Million CAD | -0.85% |
| 2023 Q1 | -380.82 Thousand CAD | 90.66% |
| 2023 Q4 | -2.88 Million CAD | -474.04% |
| 2023 Q2 | -698.08 Thousand CAD | -83.31% |
| 2023 FY | -4.46 Million CAD | 53.84% |
| 2023 Q3 | -501.76 Thousand CAD | 28.12% |
| 2022 Q4 | -4.07 Million CAD | -153.38% |
| 2022 Q3 | -1.6 Million CAD | 34.66% |
| 2022 FY | -9.66 Million CAD | -141.16% |
| 2022 Q1 | -1.51 Million CAD | -106.78% |
| 2022 Q2 | -2.46 Million CAD | -62.32% |
| 2021 Q4 | 22.36 Million CAD | 2014.47% |
| 2021 Q1 | -372.34 Thousand CAD | 82.94% |
| 2021 FY | 23.47 Million CAD | 437.69% |
| 2021 Q2 | 421.72 Thousand CAD | 213.26% |
| 2021 Q3 | 1.05 Million CAD | 150.86% |
| 2020 Q4 | -2.18 Million CAD | -794.86% |
| 2020 Q3 | 314.16 Thousand CAD | 108.04% |
| 2020 FY | -6.95 Million CAD | 23.92% |
| 2020 Q2 | -3.9 Million CAD | -232.72% |
| 2020 Q1 | -1.17 Million CAD | 66.58% |
| 2019 Q2 | -232.22 Thousand CAD | 87.84% |
| 2019 FY | -9.13 Million CAD | -664.88% |
| 2019 Q1 | -1.9 Million CAD | -205.47% |
| 2019 Q3 | -3.48 Million CAD | -1399.02% |
| 2019 Q4 | -3.51 Million CAD | -0.97% |
| 2018 Q2 | -479.08 Thousand CAD | -191.54% |
| 2018 Q3 | 2.19 Million CAD | 558.89% |
| 2018 FY | 1.61 Million CAD | -10.71% |
| 2018 Q1 | 523.34 Thousand CAD | 101.94% |
| 2018 Q4 | -625.08 Thousand CAD | -128.43% |
| 2017 Q4 | 259.16 Thousand CAD | -52.13% |
| 2017 FY | 1.81 Million CAD | 158.53% |
| 2017 Q1 | 543.11 Thousand CAD | 125.39% |
| 2017 Q2 | 473.52 Thousand CAD | -12.81% |
| 2017 Q3 | 541.34 Thousand CAD | 14.32% |
| 2016 Q1 | 267.31 Thousand CAD | 131.56% |
| 2016 Q4 | -2.13 Million CAD | -1264.27% |
| 2016 Q3 | -156.79 Thousand CAD | 85.28% |
| 2016 Q2 | -1.06 Million CAD | -498.61% |
| 2016 FY | -3.09 Million CAD | -228.58% |
| 2015 FY | -941.99 Thousand CAD | -139.22% |
| 2015 Q3 | -129.27 Thousand CAD | -148.9% |
| 2015 Q4 | -847.03 Thousand CAD | -555.23% |
| 2015 Q2 | 264.34 Thousand CAD | 215.02% |
| 2015 Q1 | -229.82 Thousand CAD | 74.74% |
| 2014 Q3 | -240.15 Thousand CAD | -155.69% |
| 2014 Q4 | -909.7 Thousand CAD | -278.8% |
| 2014 FY | 2.4 Million CAD | 341.83% |
| 2014 Q1 | 3.12 Million CAD | 2472.31% |
| 2014 Q2 | 431.21 Thousand CAD | -86.18% |
| 2013 Q2 | -558.83 Thousand CAD | 29.66% |
| 2013 Q3 | 238.82 Thousand CAD | 142.74% |
| 2013 FY | -993.16 Thousand CAD | 75.12% |
| 2013 Q4 | 121.3 Thousand CAD | -49.21% |
| 2013 Q1 | -794.48 Thousand CAD | 57.17% |
| 2012 Q3 | -732.3 Thousand CAD | -21.21% |
| 2012 Q4 | -1.85 Million CAD | -153.29% |
| 2012 FY | -3.99 Million CAD | -12.06% |
| 2012 Q1 | -800.05 Thousand CAD | 38.2% |
| 2012 Q2 | -604.14 Thousand CAD | 24.49% |
| 2011 Q2 | -430.61 Thousand CAD | 31.57% |
| 2011 Q1 | -629.24 Thousand CAD | 16.26% |
| 2011 FY | -3.56 Million CAD | 9.48% |
| 2011 Q4 | -1.29 Million CAD | -7.2% |
| 2011 Q3 | -1.2 Million CAD | -180.43% |
| 2010 Q1 | -443.35 Thousand CAD | 47.5% |
| 2010 Q4 | -751.43 Thousand CAD | -16.1% |
| 2010 Q3 | -647.22 Thousand CAD | 69.08% |
| 2010 Q2 | -2.09 Million CAD | -372.06% |
| 2010 FY | -3.93 Million CAD | 19.28% |
| 2009 FY | -4.87 Million CAD | -30.31% |
| 2009 Q1 | -1.34 Million CAD | 16.22% |
| 2009 Q3 | -1.2 Million CAD | 18.93% |
| 2009 Q2 | -1.48 Million CAD | -9.96% |
| 2009 Q4 | -844.45 Thousand CAD | 29.7% |
| 2008 Q1 | -676 Thousand CAD | 52.56% |
| 2008 FY | -3.74 Million CAD | -21.6% |
| 2008 Q3 | -498.94 Thousand CAD | 47.89% |
| 2008 Q2 | -957.57 Thousand CAD | -41.65% |
| 2008 Q4 | -1.6 Million CAD | -222.34% |
| 2007 Q1 | -401.37 Thousand CAD | 41.38% |
| 2007 Q3 | -742.6 Thousand CAD | -46.37% |
| 2007 Q4 | -1.42 Million CAD | -91.9% |
| 2007 Q2 | -507.35 Thousand CAD | -26.41% |
| 2007 FY | -3.07 Million CAD | -39.52% |
| 2006 Q3 | -518.09 Thousand CAD | 7.44% |
| 2006 FY | -2.2 Million CAD | -18.45% |
| 2006 Q4 | -684.66 Thousand CAD | -32.15% |
| 2006 Q1 | -442.48 Thousand CAD | 54.68% |
| 2006 Q2 | -559.74 Thousand CAD | -26.5% |
| 2005 Q4 | -976.27 Thousand CAD | -196.76% |
| 2005 Q2 | -378.35 Thousand CAD | -112.63% |
| 2005 FY | -1.86 Million CAD | 0.0% |
| 2005 Q1 | -177.93 Thousand CAD | 0.0% |
| 2005 Q3 | -328.98 Thousand CAD | 13.05% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Arch Biopartners Inc. | -3.32 Million CAD | -34.096% |
| Hemostemix Inc. | -2.5 Million CAD | -78.29% |
| Universal Ibogaine Inc. | -10.49 Million CAD | 57.499% |
| Kane Biotech Inc. | -5.03 Million CAD | 11.384% |
| MedMira Inc. | -2.67 Million CAD | -66.725% |
| Marvel Biosciences Corp. | -2.29 Million CAD | -94.685% |
| NervGen Pharma Corp. | -22.38 Million CAD | 80.069% |
| XORTX Therapeutics Inc. | -2.85 Million CAD | -56.013% |